202 related articles for article (PubMed ID: 25380981)
21. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
23. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
24. Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats.
Huang L; Be X; Tchaparian EH; Colletti AE; Roberts J; Langley M; Ling Y; Wong BK; Jin L
J Pharmacol Exp Ther; 2012 Nov; 343(2):316-24. PubMed ID: 22869929
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
26. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
Safar Z; Kis E; Erdo F; Zolnerciks JK; Krajcsi P
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):313-328. PubMed ID: 30856014
[TBL] [Abstract][Full Text] [Related]
27. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
[TBL] [Abstract][Full Text] [Related]
28. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
An G; Gallegos J; Morris ME
Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040
[TBL] [Abstract][Full Text] [Related]
29. Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.
Li R; Barton HA
Clin Pharmacokinet; 2018 Apr; 57(4):491-503. PubMed ID: 28653144
[TBL] [Abstract][Full Text] [Related]
30. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
31. Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo.
Zhang Y; Shipkova PA; Warrack BM; Nelson DM; Wang L; Huo R; Chen J; Panfen E; Chen XQ; Fancher RM; Ruan Q; Christopher LJ; Xue Y; Sinz M; Shen H
Drug Metab Dispos; 2023 Jul; 51(7):851-861. PubMed ID: 37055191
[TBL] [Abstract][Full Text] [Related]
32. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
Zhang D; Frost CE; He K; Rodrigues AD; Wang X; Wang L; Goosen TC; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):906-15. PubMed ID: 23386703
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.
Kusuhara H; Furuie H; Inano A; Sunagawa A; Yamada S; Wu C; Fukizawa S; Morimoto N; Ieiri I; Morishita M; Sumita K; Mayahara H; Fujita T; Maeda K; Sugiyama Y
Br J Pharmacol; 2012 Jul; 166(6):1793-803. PubMed ID: 22300367
[TBL] [Abstract][Full Text] [Related]
34. A model of secreting murine mammary epithelial HC11 cells comprising endogenous Bcrp/Abcg2 expression and function.
Tallkvist J; Yagdiran Y; Danielsson L; Oskarsson A
Cell Biol Toxicol; 2015 Apr; 31(2):111-20. PubMed ID: 25791223
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin.
Futatsugi A; Toshimoto K; Yoshikado T; Sugiyama Y; Kato Y
Drug Metab Dispos; 2018 May; 46(5):749-757. PubMed ID: 29440178
[TBL] [Abstract][Full Text] [Related]
36. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
Kashihara Y; Ieiri I; Yoshikado T; Maeda K; Fukae M; Kimura M; Hirota T; Matsuki S; Irie S; Izumi N; Kusuhara H; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2688-2694. PubMed ID: 28322941
[TBL] [Abstract][Full Text] [Related]
37. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).
Liao M; Chuang BC; Zhu Q; Li Y; Guan E; Yu S; Yang J; Prakash S; Xia CQ
Xenobiotica; 2018 May; 48(5):467-477. PubMed ID: 28485193
[TBL] [Abstract][Full Text] [Related]
38. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Humphreys JE; Lou Y; Lee EJ
J Pharm Sci; 2010 Feb; 99(2):1046-62. PubMed ID: 19569219
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
Tang SC; Lankheet NA; Poller B; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2012 Apr; 341(1):164-73. PubMed ID: 22238213
[TBL] [Abstract][Full Text] [Related]
40. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
